Actionable news
All posts from Actionable news
Actionable news in FGEN: FIBROGEN INC,

FibroGen Reports Second Quarter 2017 Financial Results

Company Announces Positive Topline Results from Phase 2 Study in IPF

Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time

SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN), a science-based biopharmaceutical company, today reported financial results for the second quarter of 2017 and announced positive topline results of the company’s Phase 2 randomized, double-blind, placebo-controlled study and two combination sub-studies of pamrevlumab in idiopathic pulmonary fibrosis (IPF). Pamrevlumab is a proprietary anti-connective tissue growth factor (CTGF) antibody being evaluated in fibrotic disease and cancer.

“We are very encouraged by the topline IPF Phase 2 clinical study results that we announced today, in which pamrevlumab-treated patients had a significantly lower rate of decline in lung function, as compared to the placebo-treated patients. In addition, pamrevlumab continued to be well tolerated as a monotherapy in this IPF study, and was well tolerated in combination with pirfenidone and nintedanib,” said Thomas B. Neff, FibroGen’s Chief Executive Officer. “We believe that the promising outcomes of these studies enable us to advance pamrevlumab into Phase 3 clinical development.”

Recent Developments
Pamrevlumab for Idiopathic Pulmonary Fibrosis (IPF)

  • Reported positive topline Phase 2 clinical results from a double-blind, placebo-controlled study, and two double-blind, active-controlled combination sub-studies

Pamrevlumab for Pancreatic Cancer

  • Orphan Drug Designation status was granted by the U.S. Food and Drug Administration (FDA)
  • Phase 2 clinical results are expected year-end 2017/first quarter 2018

Roxadustat for Anemia in Chronic Kidney Disease (CKD)

  • On track to submit the new drug application (NDA) to the FDA in 2018
  • The independent data safety monitoring board, which reviews the U.S. and...